Literature DB >> 12036742

How protozoan parasites evade the immune response.

Sergio Zambrano-Villa1, Disney Rosales-Borjas, Julio César Carrero, Librado Ortiz-Ortiz.   

Abstract

Protozoan pathogens such as Plasmodium, Leishmania, Trypanosoma and Entamoeba are responsible for several of the most widespread and lethal human diseases. Their successful survival depends mainly on evading the host immune system by, for example, penetrating and multiplying within cells, varying their surface antigens, eliminating their protein coat, and modulating the host immune response. Immunosuppression is sometimes caused directly by parasite products and sometimes involves antigenic mimicry, which often appears in association with parasitic diseases. However, one of the most sophisticated mechanisms of evasion is the selective activation of a subset of T helper cells.

Entities:  

Mesh:

Year:  2002        PMID: 12036742     DOI: 10.1016/s1471-4922(02)02289-4

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  47 in total

1.  Leishmania major chromosome 3 contains two long convergent polycistronic gene clusters separated by a tRNA gene.

Authors:  E A Worthey; Santiago Martinez-Calvillo; Achim Schnaufer; Gautam Aggarwal; Jason Cawthra; Gholam Fazelinia; Chris Fong; Guoliang Fu; Melissa Hassebrock; Greg Hixson; Alasdair C Ivens; Patti Kiser; Felicia Marsolini; Erika Rickel; Erica Rickell; Reza Salavati; Ellen Sisk; Susan M Sunkin; Kenneth D Stuart; Peter J Myler
Journal:  Nucleic Acids Res       Date:  2003-07-15       Impact factor: 16.971

2.  Antigenic diversity is generated by distinct evolutionary mechanisms in African trypanosome species.

Authors:  Andrew P Jackson; Andrew Berry; Martin Aslett; Harriet C Allison; Peter Burton; Jana Vavrova-Anderson; Robert Brown; Hilary Browne; Nicola Corton; Heidi Hauser; John Gamble; Ruth Gilderthorp; Lucio Marcello; Jacqueline McQuillan; Thomas D Otto; Michael A Quail; Mandy J Sanders; Andries van Tonder; Michael L Ginger; Mark C Field; J David Barry; Christiane Hertz-Fowler; Matthew Berriman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-13       Impact factor: 11.205

3.  Humoral and cellular immune responses in BALB/c and C57BL/6 mice immunized with cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens, in acute experimental Trypanosoma cruzi infection.

Authors:  Valéria R A Pereira; Virginia M B Lorena; Mineo Nakazawa; Carlos F Luna; Edimilson D Silva; Antonio G P Ferreira; Marco Aurélio Krieger; Samuel Goldenberg; Milena B P Soares; Eridan M Coutinho; Rodrigo Correa-Oliveira; Yara M Gomes
Journal:  Parasitol Res       Date:  2005-04-27       Impact factor: 2.289

4.  Molecular characterization of a human BRCA2 homolog in Leishmania donovani.

Authors:  Smita Misra; Mack Hall; Gautam Chaudhuri
Journal:  J Parasitol       Date:  2005-12       Impact factor: 1.276

Review 5.  Host-parasite interactions in trypanosomiasis: on the way to an antidisease strategy.

Authors:  Nicolas Antoine-Moussiaux; Philippe Büscher; Daniel Desmecht
Journal:  Infect Immun       Date:  2009-01-21       Impact factor: 3.441

Review 6.  Toll-like receptors and leishmaniasis.

Authors:  Felipe F Tuon; Valdir S Amato; Hélio A Bacha; Tariq Almusawi; Maria I Duarte; Vicente Amato Neto
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

7.  Intriguing parasites and intramembrane proteases.

Authors:  Robert B Rawson
Journal:  Genes Dev       Date:  2008-06-15       Impact factor: 11.361

8.  Intestinal invasion by Entamoeba histolytica.

Authors:  Shahram Solaymani-Mohammadi; William A Petri
Journal:  Subcell Biochem       Date:  2008

9.  Inoculating Anopheles gambiae Mosquitoes with Beads to Induce and Measure the Melanization Immune Response.

Authors:  Antoine M G Barreaux; Priscille Barreaux; Matthew B Thomas; Jacob C Koella
Journal:  J Vis Exp       Date:  2017-01-12       Impact factor: 1.355

Review 10.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.